よむ、つかう、まなぶ。
04資料２ 新型コロナワクチンに関する資料 (79 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000192554_00026.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会（第51回 1／26）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
https://doi.org:10.1056/NEJMoa2113017
26
Tseng, H. F. et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta
variants. Nat Med 28, 1063-1071 (2022). https://doi.org:10.1038/s41591-022-01753-y
27
Heath, P. T. et al. Safety and Efficacy of the NVX-CoV2373 COVID-19 Vaccine at
Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial. Clin
Infect Dis (2022). https://doi.org:10.1093/cid/ciac803
28
Moreira, E. D., Jr. et al. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19
Vaccine. N Engl J Med 386, 1910-1921 (2022). https://doi.org:10.1056/NEJMoa2200674
29
Barda, N. et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine
for preventing severe outcomes in Israel: an observational study. Lancet 398, 2093-2100
(2021). https://doi.org:10.1016/S0140-6736(21)02249-2
30
Bar-On, Y. M. et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.
N Engl J Med 385, 1393-1400 (2021). https://doi.org:10.1056/NEJMoa2114255
31
Heath, P. T. et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med
385, 1172-1183 (2021). https://doi.org:10.1056/NEJMoa2107659
32
Alves, K. et al. Immunogenicity and safety of a 4th homologous booster dose of a SARSCoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2, randomized,
placebo-controlled
medRxiv,
trial.
2022.2011.2018.22282414
(2022).
https://doi.org:10.1101/2022.11.18.22282414
33
Walter, E. B. et al. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11
Years of Age. N Engl J Med 386, 35-46 (2022). https://doi.org:10.1056/NEJMoa2116298
34
Price, A. M. et al. BNT162b2 Protection against the Omicron Variant in Children and
N
Adolescents.
Engl
J
Med
386,
1899-1909
(2022).
https://doi.org:10.1056/NEJMoa2202826
35
Fleming-Dutra, K. E. et al. Association of Prior BNT162b2 COVID-19 Vaccination With
Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron
Predominance. JAMA 327, 2210-2219 (2022). https://doi.org:10.1001/jama.2022.7493
36
Cohen-Stavi, C. J. et al. BNT162b2 Vaccine Effectiveness against Omicron in Children 5
to
11
Years
of
N
Age.
Engl
J
Med
387,
227-236
(2022).
https://doi.org:10.1056/NEJMoa2205011
37
Sacco, C. et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and
severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of JanuaryApril, 2022. Lancet 400, 97-103 (2022). https://doi.org:10.1016/S0140-6736(22)011850
38
Tan, S. H. X. et al. Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to
11
Years
of
Age.
N
Engl
79
J
Med
387,
525-532
(2022).
26
Tseng, H. F. et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta
variants. Nat Med 28, 1063-1071 (2022). https://doi.org:10.1038/s41591-022-01753-y
27
Heath, P. T. et al. Safety and Efficacy of the NVX-CoV2373 COVID-19 Vaccine at
Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial. Clin
Infect Dis (2022). https://doi.org:10.1093/cid/ciac803
28
Moreira, E. D., Jr. et al. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19
Vaccine. N Engl J Med 386, 1910-1921 (2022). https://doi.org:10.1056/NEJMoa2200674
29
Barda, N. et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine
for preventing severe outcomes in Israel: an observational study. Lancet 398, 2093-2100
(2021). https://doi.org:10.1016/S0140-6736(21)02249-2
30
Bar-On, Y. M. et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.
N Engl J Med 385, 1393-1400 (2021). https://doi.org:10.1056/NEJMoa2114255
31
Heath, P. T. et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med
385, 1172-1183 (2021). https://doi.org:10.1056/NEJMoa2107659
32
Alves, K. et al. Immunogenicity and safety of a 4th homologous booster dose of a SARSCoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2, randomized,
placebo-controlled
medRxiv,
trial.
2022.2011.2018.22282414
(2022).
https://doi.org:10.1101/2022.11.18.22282414
33
Walter, E. B. et al. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11
Years of Age. N Engl J Med 386, 35-46 (2022). https://doi.org:10.1056/NEJMoa2116298
34
Price, A. M. et al. BNT162b2 Protection against the Omicron Variant in Children and
N
Adolescents.
Engl
J
Med
386,
1899-1909
(2022).
https://doi.org:10.1056/NEJMoa2202826
35
Fleming-Dutra, K. E. et al. Association of Prior BNT162b2 COVID-19 Vaccination With
Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron
Predominance. JAMA 327, 2210-2219 (2022). https://doi.org:10.1001/jama.2022.7493
36
Cohen-Stavi, C. J. et al. BNT162b2 Vaccine Effectiveness against Omicron in Children 5
to
11
Years
of
N
Age.
Engl
J
Med
387,
227-236
(2022).
https://doi.org:10.1056/NEJMoa2205011
37
Sacco, C. et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and
severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of JanuaryApril, 2022. Lancet 400, 97-103 (2022). https://doi.org:10.1016/S0140-6736(22)011850
38
Tan, S. H. X. et al. Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to
11
Years
of
Age.
N
Engl
79
J
Med
387,
525-532
(2022).